中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (11): 869-874.doi: 10.35541/cjd.20200306
中国医师协会皮肤科医师分会自身免疫性疾病专业委员会
收稿日期:
2020-03-30
修回日期:
2020-06-12
发布日期:
2020-11-03
通讯作者:
邓丹琪;左亚刚
E-mail:danqid128@sina.com;zuoyagang@263.net
Committee on Autoimmune Diseases, China Dermatologist Association
Received:
2020-03-30
Revised:
2020-06-12
Published:
2020-11-03
Contact:
Deng Danqi; Zuo Yagang
E-mail:danqid128@sina.com;zuoyagang@263.net
摘要: 【摘要】 吗替麦考酚酯可选择性抑制T、B淋巴细胞的增殖和活性,已广泛应用于多种免疫相关性皮肤病的治疗。在检索国内外文献的基础上,中国不同地域多位专家讨论和撰写了本建议。根据英国牛津大学循证医学中心制定的推荐等级标准,吗替麦考酚酯在成人中重度寻常型斑块状银屑病、成人大疱性类天疱疮和寻常型天疱疮的治疗中属于A级推荐;在成人系统性硬化症、成人中重度湿疹和中重度特应性皮炎的治疗中均属于B级推荐;在皮肤型红斑狼疮、皮肌炎、无肌病性皮肌炎、儿童系统性硬化症、儿童大疱性类天疱疮和儿童天疱疮、儿童中重度湿疹和特应性皮炎的治疗中属于C级推荐。
中国医师协会皮肤科医师分会自身免疫性疾病专业委员会. 吗替麦考酚酯治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2020,53(11):869-874. doi:10.35541/cjd.20200306
Committee on Autoimmune Diseases, China Dermatologist Association. Mycophenolate mofetil in the treatment of immune?related skin diseases: an expert proposal[J]. Chinese Journal of Dermatology, 2020, 53(11): 869-874.doi:10.35541/cjd.20200306
[1] | 吗替麦考酚酯在肾内科应用专家共识组. 吗替麦考酚酯在肾内科应用专家共识——2006年第四次修订[J]. 中华内科杂志, 2006,45(11):965⁃966. doi: 10.3760/j.issn:0578⁃1426.2006. 11.036. |
[2] | 吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识小组. 吗替麦考酚酯在自身免疫病治疗中应用的风湿病专家共识[J]. 中华风湿病学杂志, 2019,23(7):436⁃440. doi: 10. 3760/cma.j.issn.1007⁃7480.2019.07.002. |
[3] | Thervet E, Anglicheau D, Legendre C. Pharmacology of mycophenolate mofetil: recent data and clinical consequences[J]. Nephrologie, 2001,22(7):331⁃337. |
[4] | Liu YX, Jin LM, Zhou L, et al. Mycophenolate mofetil attenuates liver ischemia/reperfusion injury in rats[J]. Transpl Int, 2009,22(7):747⁃756. doi: 10.1111/j.1432⁃2277.2009.00866.x. |
[5] | Nakaseko H, Iwata N, Yasuoka R, et al. Pharmacokinetics of mycophenolate mofetil in juvenile patients with autoimmune diseases[J]. Mod Rheumatol, 2019,29(6):1002⁃1006. doi: 10. 1080/14397595.2018.1532785. |
[6] | Li H, Mager DE, Sandmaier BM, et al. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil[J]. J Clin Pharmacol, 2013,53(4):393⁃402. doi: 10.1002/jcph.14. |
[7] | Pescovitz MD, Conti D, Dunn J, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics[J]. Clin Transplant, 2000,14(3):179⁃188. doi: 10.1034/j.1399⁃0012.2000.140301.x. |
[8] | Kuhn A, Aberer E, Bata⁃Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus ⁃ guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)[J]. J Eur Acad Dermatol Venereol, 2017,31(3):389⁃404. doi: 10.1111/jdv.14053. |
[9] | Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid⁃sparing therapy for recalcitrant dermatomyositis[J]. Arch Dermatol, 2006,142(1):65⁃69. doi: 10.1001/archderm.142.1.65. |
[10] | Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists[J]. Mod Rheumatol, 2019,29(1):1⁃19. doi: 10.1080/14397595.2018.15 21185. |
[11] | Sunderkötter C, Nast A, Worm M, et al. Guidelines on dermatomyositis⁃⁃excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology[J]. J Dtsch Dermatol Ges, 2016,14(3):321⁃338. doi: 10.1111/ddg.12909. |
[12] | Cozzani E, Cinotti E, Felletti R, et al. Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil[J]. Immunopharmacol Immunotoxicol, 2013,35(6):687⁃692. doi: 10.3109/08923973.2013.833624. |
[13] | Hayashi M, Kikuchi T, Takada T. Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti⁃MDA⁃5 antibodies[J]. Clin Rheumatol, 2017,36(1):239⁃240. doi: 10.1007/s10067⁃016⁃3443⁃2. |
[14] | Koyama R, Braga T, da Silva Dias GA, et al. Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case⁃based review[J]. Clin Rheumatol, 2017,36(8):1919⁃1926. doi: 10.1007/s10067⁃017⁃3671⁃0. |
[15] | Bellutti Enders F, Bader⁃Meunier B, Baildam E, et al. Consensus⁃based recommendations for the management of juvenile dermatomyositis[J]. Ann Rheum Dis, 2017,76(2):329⁃340. doi: 10.1136/annrheumdis⁃2016⁃209247. |
[16] | Taroni JN, Martyanov V, Mahoney JM, et al. A functional genomic meta⁃analysis of clinical trials in systemic sclerosis: toward precision medicine and combination therapy[J]. J Invest Dermatol, 2017,137(5):1033⁃1041. doi: 10.1016/j.jid.2016.12. 007. |
[17] | Gale SL, Trinh H, Mathew N, et al. Characterizing disease manifestations and treatment patterns among adults with systemic sclerosis: a retrospective analysis of a US healthcare claims population[J]. Rheumatol Ther, 2020,7(1):89⁃99. doi:10.1007/s40744⁃019⁃00181⁃8. |
[18] | Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma⁃related interstitial lung disease (SLS II): a randomised controlled, double⁃blind, parallel group trial[J]. Lancet Respir Med, 2016,4(9):708⁃719. doi: 10.1016/S2213⁃2600(16)30152⁃7. |
[19] | Mendoza FA, Lee⁃Ching C, Jimenez SA. Recurrence of progressive skin involvement following discontinuation or dose reduction of mycophenolate mofetil treatment in patients with diffuse systemic sclerosis[J]. Semin Arthritis Rheum, 2020,50(1):135⁃139. doi: 10.1016/j.semarthrit.2019.06.012. |
[20] | Kowal⁃Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Ann Rheum Dis, 2017,76(8):1327⁃1339. doi: 10.1136/annrheumdis⁃2016⁃209909. |
[21] | Asano Y, Jinnin M, Kawaguchi Y, et al. Diagnostic criteria, severity classification and guidelines of systemic sclerosis[J]. J Dermatol, 2018,45(6):633⁃691. doi: 10.1111/1346⁃8138.14162. |
[22] | Rabinovich CE. Challenges in the diagnosis and treatment of juvenile systemic sclerosis[J]. Nat Rev Rheumatol, 2011,7(11):676⁃680. doi: 10.1038/nrrheum.2011.148. |
[23] | Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology[J]. Br J Dermatol, 2015,172(4):867⁃877. doi: 10.1111/bjd.13717. |
[24] | Cozzani E, Marzano AV, Caproni M, et al. Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines[J]. G Ital Dermatol Venereol, 2018,153(3):305⁃315. doi: 10.23736/S0392⁃0488.18.06006⁃6. |
[25] | Santi CG, Gripp AC, Roselino AM, et al. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita ⁃ Brazilian Society of Dermatology[J]. An Bras Dermatol, 2019,94(2 Suppl 1):33⁃47. doi: 10.1590/abd1806⁃4841.2019940207. |
[26] | Eming R, Sticherling M, Hofmann SC, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid[J]. J Dtsch Dermatol Ges, 2015,13(8):833⁃844. doi: 10.1111/ddg.12606. |
[27] | 中国医师协会皮肤科医师分会自身免疫性疾病亚专业委员会. 大疱性类天疱疮诊断和治疗的专家建议[J]. 中华皮肤科杂志, 2016,49(6):384⁃387. doi: 10.3760/cma.j.issn.0412⁃4030. 2016.06.003. |
[28] | Seminario⁃Vidal L, Sami N, Miller J, et al. Mycophenolate mofetil therapy for pediatric bullous pemphigoid[J]. Dermatol Online J, 2015,21(8):13030/qt3x5585zn. |
[29] | Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment⁃⁃guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)[J]. J Eur Acad Dermatol Venereol, 2015,29(3):405⁃414. doi: 10.1111/jdv.12772. |
[30] | Feliciani C, Cozzani E, Marzano AV, et al. Italian guidelines in pemphigus⁃adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV)[J]. G Ital Dermatol Venereol, 2018,153(5):599⁃608. doi: 10.23736/S0392⁃0488.18.06073⁃X. |
[31] | Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists′ guidelines for the management of pemphigus vulgaris 2017[J]. Br J Dermatol, 2017,177(5):1170⁃1201. doi: 10.1111/bjd.15930. |
[32] | 中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议(2020)[J]. 中华皮肤科杂志, 2020,53(1):1⁃7. doi: 10.35541/cjd.20190703. |
[33] | Baratta A, Camarillo D, Papa C, et al. Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF)[J]. Pediatr Dermatol, 2013,30(2):240⁃244. doi: 10.1111/j.1525⁃1470.2012.01730.x. |
[34] | Haeck IM, Knol MJ, Ten Berge O, et al. Enteric⁃coated mycophenolate sodium versus cyclosporin A as long⁃term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial[J]. J Am Acad Dermatol, 2011,64(6):1074⁃1084. doi: 10.1016/j.jaad.2010.04.027. |
[35] | Prussick L, Plotnikova N, Gottlieb A. Mycophenolate mofetil in severe atopic dermatitis: a review[J]. J Drugs Dermatol, 2016,15(6):715⁃718. |
[36] | Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients[J]. J Eur Acad Dermatol Venereol, 2016,30(5):729⁃747. doi: 10.1111/jdv.13599. |
[37] | Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part Ⅱ[J]. J Eur Acad Dermatol Venereol, 2018,32(6):850⁃878. doi: 10.1111/jdv.14888. |
[38] | Heller M, Shin HT, Orlow SJ, et al. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients[J]. Br J Dermatol, 2007,157(1):127⁃132. doi: 10.1111/j.1365⁃2133.2007.07947.x. |
[39] | Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil[J]. Pediatr Dermatol, 2011,28(6):689⁃694. doi: 10. 1111/j.1525⁃1470.2011.01488.x. |
[40] | Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents[J]. J Am Acad Dermatol, 2009,61(3):451⁃485. doi: 10.1016/j.jaad.2009.03.027. |
[41] | Akhyani M, Chams⁃Davatchi C, Hemami MR, et al. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis[J]. J Eur Acad Dermatol Venereol, 2010,24(12):1447⁃1451. doi: 10.1111/j.1468⁃3083. 2010.03667.x. |
[42] | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2018完整版)[J]. 中华皮肤科杂志, 2019,52(10):667⁃710. doi: 10.35541/cjd.20190847. |
[43] | Liu V, Mackool BT. Mycophenolate in dermatology[J]. J Dermatolog Treat, 2003,14(4):203⁃211. doi: 10.1080/0954663 0310016826. |
[44] | US FDA. Highlights of prescribing information: CELLCEPT®[EB/OL]. (2018⁃08⁃30) [2020⁃06⁃12]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050722s040,050723s041,050758s037,050759s045lbl.pdf. |
[45] | Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis[J]. Arthritis Care Res (Hoboken), 2012,64(6):797⁃808. doi: 10.1002/acr.21664. |
[46] | Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association⁃European Dialysis and Transplant Association (EULAR/ERA⁃EDTA) recommendations for the management of adult and paediatric lupus nephritis[J]. Ann Rheum Dis, 2012,71(11):1771⁃1782. doi: 10.1136/annrheumdis⁃2012⁃201940. |
[47] | Benjanuwattra J, Pruksakorn D, Koonrungsesomboon N. Mycophenolic acid and its pharmacokinetic drug⁃drug interactions in humans: review of the evidence and clinical implications[J]. J Clin Pharmacol, 2020,60(3):295⁃311. doi: 10.1002/jcph.1565. |
[48] | Kuypers DR, Verleden G, Naesens M, et al. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate⁃glucuronosyltransferase[J]. Clin Pharmacol Ther, 2005,78(1):81⁃88. doi: 10.1016/j.clpt.2005.03. 004. |
[49] | Gimenez F, Foeillet E, Bourdon O, et al. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects[J]. Clin Pharmacokinet, 2004,43(10):685⁃692. doi: 10.2165/00003088⁃200443100⁃00004. |
[1] | 刘小扬 赵琰 蔡林 张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848. |
[2] | 郭昊 刘辉 张丽 朱冠男 王平 姚志荣 高兴华 陈耀龙. 特应性皮炎诊疗指南(专科医生版本、全科医生版本和患者版本)计划书[J]. 中华皮肤科杂志, 2023, 56(9): 809-814. |
[3] | 付丹丹 李佳林 付修宇 张芯育 胡华 宋向凤 田中伟. S100A10蛋白在银屑病皮损的表达及对小鼠银屑病样皮炎模型的影响[J]. 中华皮肤科杂志, 2023, 56(9): 839-844. |
[4] | 陈春里 闫思聿 王丹 高丽华 谭丽娜 唐四元 刘伟 曾金容 鲁建云. 酸化脂肪酸酯治疗特应性皮炎样模型小鼠的疗效及机制初探[J]. 中华皮肤科杂志, 2023, 56(9): 822-831. |
[5] | 荆可 王媛 李锁 冯素英. 表现为环状红斑水疱的自身免疫性表皮下水疱病25例回顾性分析[J]. 中华皮肤科杂志, 2023, 56(9): 832-838. |
[6] | 王珊 王星宇 舒虹 张斌 石航 杨欢 钱秋芳 马红艳 梁源 赵牧童 申春平 焦磊 田晶 汪洋 谷盈 孙婧 刘盈 李萍 王华 马琳. 克立硼罗软膏早期缓解儿童特应性皮炎临床症状及改善缓解期临床症状的多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(9): 815-821. |
[7] | 申春平 李萍 罗晓燕 梁源 刘盈 赵牧童 王珊 田晶 焦磊 汪洋 罗珍 余时娟 方晓 王华 马琳. [开放获取] 某润肤霜联合周末外用糖皮质激素对延缓儿童特应性皮炎维持期疾病复发的随机、空白对照、多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(8): 756-762. |
[8] | 徐西利 李东宁 段函 王菲. 青少年及成人特应性皮炎患者血浆氨基酸代谢水平分析[J]. 中华皮肤科杂志, 2023, 56(8): 742-750. |
[9] | 宋志强 陈奇权 葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723. |
[10] | 周彤 耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793. |
[11] | 陈小敏 张景展 丁媛 康晓静. 二甲双胍治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(8): 799-802. |
[12] | 王俊霞 郭伟楠 陈慧 郝军峰 李冰 卫静宜 赵涛. 自体脂肪移植治疗40例稳定期线状硬斑病疗效回顾分析[J]. 中华皮肤科杂志, 2023, 56(8): 762-765. |
[13] | 张晓东 汪蔓雅 朱英杰 骆天德 刘小明. 荧光染色法在面部皮肤蠕形螨检查中的应用评估[J]. 中华皮肤科杂志, 2023, 56(8): 766-769. |
[14] | 王莉 任增果 娄桂予 张玉薇 杨科 雷星星 张冰 廖世秀 郝冰涛. 两个营养不良型大疱性表皮松解症家系的基因诊断[J]. 中华皮肤科杂志, 2023, 56(8): 770-773. |
[15] | 唐志铭 荆梦晴 陆鹭 单霄 张翠侠 张晓宇 孟飒. 犀地凉血方通过LncRNA NEAT1/miR-485-5p/ STAT3调控网络对HaCaT细胞增殖、凋亡影响的研究[J]. 中华皮肤科杂志, 2023, 56(7): 642-650. |
|